Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity

Follicular Lymphoma Clinical Trial

Official title:

Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity Following CAR-T Infusion on an Outpatient Basis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04503538
• Other study ID #: IRB00067341
• Secondary ID: WFBCCC 99520
• Status: Withdrawn
• Phase: N/A
• Start date: December 2020
• Est. completion date: November 2023

Study information

• Verified date: October 2020
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to replace one of participants' outpatient chimeric antigen receptor T-cell (CAR-T) therapy follow up visits with a virtual or "telemedicine" visit. The telemedicine visit will use an electronic tablet with a camera and a microphone that allows participants to communicate with their physicians and nurses. Participants will be provided with the necessary equipment to complete these visits.

Description:

Primary Objective: To determine feasibility of telemedicine for outpatient cytokine release syndrome and neurotoxicity assessment (how many telemedicine visits successfully completed per patient)

Secondary Objective(s)

• To determine how many times a telemedicine visit triggered an action (inpatient admission/ outpatient observation status)

• To determine how many patients were detected to have cytokine release syndrome and/or neurotoxicity based on their telemedicine visit

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2023
• Est. primary completion date: September 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologically confirmed relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from of follicular lymphoma

• Age = 18 years

• ECOG or Karnofsky performance status of = 2

• Patients must have a caregiver(s) with them 24 hours a day for the first 30 days after CAR-T cell infusion

• Patients must stay within a 30-minute distance from the cancer center

• Patients must have access to wifi network or a cellular network

• Patients and caregiver(s) participating in patient's care must attend the education session for outpatient CAR-T and demonstrate competency to collect vital signs with equipment provided

• Must have the ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).

Exclusion Criteria:

• Patients who have acute lymphoblastic leukemia/lymphoma

• Patients who have a high tumor burden (> 10 cm largest mass) have a high risk of CRS who will receive CAR-T as an inpatient

• Patient or caregiver unable to understand and follow English language

• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Related Conditions & MeSH terms

• Diffuse Large B Cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Large B-cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Neurotoxicity Syndromes
• Primary Mediastinal Large B Cell Lymphoma

Intervention

Other:
• Telemedicine visit
Participants will be provided with a Wifi-and cellular enabled electronic tablet. Additionally, participants will receive a kit that contains a thermometer, a blood pressure monitoring cuff, and a pulse oximeter (to measure oxygen saturation level). Participants will attend an educational session to learn how the telemedicine visit works. Caregivers should attend with participants and will be trained to take temperatures, blood pressures, and oxygen saturation levels. Participants will also be asked to complete a test telehealth visit.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Successfully Completed Telemedicine Visits	To determine feasibility of telemedicine for outpatient cytokine release syndrome and neurotoxicity assessment. Investigators will consider telemedicine feasible in this population if at least 13 of the 15 patients successfully complete 80% of telemedicine visits. A visit will be considered successful if all measurements are recorded OR if the visit is interrupted because the participant needs to come into the CAR-T unit for assessment. If a patient is admitted, then the 80% benchmark will be calculated based on the number of days the patient was outpatient at 11 pm. The proportion meeting the 80% benchmark will be reported along with an exact 95% confidence interval.	3 years
Secondary	Number of Times a Telemedicine Visit Triggered Action	To determine how many times a telemedicine visit triggered an inpatient admission or outpatient observation status	3 years
Secondary	Number of Patients to Have Cytokine Release Syndrome	Descriptive statistics will be used to characterize the number of cases of cytokine release syndrome based on telemedicine visits.	3 years
Secondary	Number of Patients to Have Neurotoxicity	Descriptive statistics will be used to characterize the number neurotoxicities reported based on telemedicine visits.	3 years